Department of Ophthalmology & Visual Sciences. Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil; Instituto de Medicina Tropical, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Int J Infect Dis. 2024 Sep;146:107071. doi: 10.1016/j.ijid.2024.107071. Epub 2024 May 6.
We describe the clinical presentation and ocular viral dynamics in patients with Monkeypox virus-related ophthalmic disease (MPXROD).
In this case series, we investigated five consecutive patients with confirmed mpox, diagnosed through a positive Monkeypox virus (MPXV) Polymerase Chain Reaction (PCR) test and presenting with ocular symptoms. They were referred from the Reference Center for Sexually Transmitted Infections in São Paulo (CRT) to the Uveitis Sector at the Federal University of São Paulo, between August and December 2022. We performed PCR testing on ocular samples and culture supernatants for MPXV in all patients. Viral sequencing was conducted in one of the cases.
Replicating MPXV was identified in at least one ocular sample of all patients, between day 31 and day 145 after the onset of skin lesions. All patients presented with keratitis, 3 with uveitis (60%) and two exhibited hypopyon (40%). The onset of ocular symptoms occurred at a mean of 21.2 days after the appearance of the first skin lesion and persisted, on average, for 61,.6 days, with a worsening trend observed until the initiation of tecovirimat treatment. Tecovirimat treatment was administered to all patients, with initiation occurring between 31 and 145 days after the onset of skin lesions. MPXV genome sequencing of an isolate from one patient classified it as belonging to lineage B1 in clade IIb.
This study reveals a late onset and persistence of sight threatening ocular disease, along with potential viral infectivity even after systemic resolution in mpox cases. These findings highlight the risk of ongoing transmission from individuals with prolonged ocular manifestations, particularly through ocular discharge.
我们描述了与猴痘病毒相关眼病(MPXROD)相关的患者的临床症状和眼部病毒动力学。
在本病例系列研究中,我们调查了 5 例连续确诊的猴痘患者,他们通过阳性猴痘病毒(MPXV)聚合酶链反应(PCR)检测和眼部症状被诊断为 MPXV 感染。他们于 2022 年 8 月至 12 月期间从圣保罗性传播感染参考中心(CRT)转至圣保罗联邦大学葡萄膜炎科。我们对所有患者的眼部样本和培养上清液进行了 MPXV 的 PCR 检测。在一个病例中进行了病毒测序。
在所有患者中,至少有一个眼部样本中检测到复制的 MPXV,时间在皮肤损伤出现后第 31 天至第 145 天之间。所有患者均出现角膜炎,3 例(60%)出现葡萄膜炎,2 例(40%)出现前房积脓。眼部症状的发作平均发生在首次皮肤损伤出现后 21.2 天,持续时间平均为 61.6 天,在开始使用特考韦瑞姆治疗之前,症状有加重趋势。所有患者均接受了特考韦瑞姆治疗,开始治疗的时间为皮肤损伤出现后第 31 天至第 145 天之间。对一名患者的分离株进行的 MPXV 基因组测序将其归类为属于 IIb 分支的 B1 谱系。
本研究揭示了在猴痘病例中,眼部疾病的发病晚且持续存在,甚至在全身症状缓解后仍存在潜在的病毒传染性。这些发现强调了具有长期眼部表现的个体持续传播的风险,特别是通过眼部分泌物。